

O c t o b e r 3 1 , 2 0 0 8

**Application filed for a transdermal patch containing buprenorphine designed to control moderate to severe, chronic lower back and osteoarthritis pain
(Development code: BTDS)**

Hisamitsu Pharmaceutical Co., Inc. (Hisamitsu; TSE:4530) today announced that Mundipharma K.K., Japan (Mundipharma K.K.) has filed an application for new drug approval with Ministry of Health, Labour and Welfare on a transdermal patch containing buprenorphine (Development code: BTDS).

Hisamitsu acquired the exclusive sales and distribution rights for Japan for BTDS from Mundipharma International Limited in August, 2007.

BTDS is a transdermal patch containing buprenorphine designed to control moderate to severe, chronic lower back and osteoarthritis pain, which cannot be well managed by a non-steroidal anti-inflammatory drug (“NSAIDs”).

When the product has been approved, Hisamitsu will carry out marketing, distribution, and sales activities.